Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
暂无分享，去创建一个
R. Greil | L. Bullinger | K. Döhner | R. Schlenk | H. Döhner | V. Gaidzik | P. Paschka | M. Heuser | F. Thol | A. Ganser | K. Götze | U. Martens | A. Benner | M. Lübbert | W. Fiedler | S. Cocciardi | E. Koller | D. Nachbaur | K. Mayer | J. Krauter | G. Wulf | B. Hertenstein | Maral Saadati | M. Ringhoffer | Anika Schrade | M. Wattad | T. Schroeder | D. Weber | J. Krzykalla | J. Schleicher | N. Basara | M. Kühn | S. Kapp-Schwoerer | Claudia Leis | S. Machherndl-Spandl | Lars Fransecky | Maisun Abu Samra